EPS for ACADIA Pharmaceuticals Inc. (ACAD) Expected At $-0.56

Investors sentiment decreased to 0.92 in 2018 Q3. Its down 0.30, from 1.22 in 2018Q2. It dropped, as 31 investors sold ACADIA Pharmaceuticals Inc. shares while 45 reduced holdings. 31 funds opened positions while 39 raised stakes. 116.41 million shares or 1.85% more from 114.30 million shares in 2018Q2 were reported.
Glenmede Tru Na holds 4,055 shares. Profund Advsr Limited Liability Corporation holds 0.03% or 36,309 shares. Tiaa Cref Investment Mgmt reported 565,674 shares. Sei Invs, a Pennsylvania-based fund reported 14,831 shares. Fosun reported 0.22% stake. Lpl Ltd Limited Liability Company stated it has 0.01% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Hudson Bay Capital Mgmt Ltd Partnership has invested 0.01% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Moreover, Point72 Asset Management Lp has 0.15% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 1.81M shares. Weiss Multi holds 0.08% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 140,000 shares. Gofen & Glossberg Limited Liability Co Il has 0.01% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Wells Fargo And Mn invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Ameritas Inv Partners Inc has invested 0.01% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Qs Ltd Liability Corporation has 0.04% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Amer Century has 0% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 147,949 shares. Goldman Sachs Gp holds 0.01% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) or 1.28M shares.

Since September 20, 2018, it had 2 insider buys, and 1 sale for $222.45 million activity. BAKER BROS. ADVISORS LP bought $22.65 million worth of stock.

Analysts expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report $-0.56 EPS on February, 26.They anticipate $0.01 EPS change or 1.82 % from last quarter’s $-0.55 EPS. After having $-0.50 EPS previously, ACADIA Pharmaceuticals Inc.’s analysts see 12.00 % EPS growth. The stock decreased 1.16% or $0.27 during the last trading session, reaching $22.98. About 300 shares traded. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 37.59% since February 20, 2018 and is downtrending. It has underperformed by 37.59% the S&P500.

– Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company has market cap of $3.30 billion. The Company’s lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer’s disease psychosis. It currently has negative earnings. The firm has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain.

More notable recent ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news were published by: Nasdaq.com which released: “The Smartest People on Wall Street Are Buying These 3 Stocks — Should You? – Nasdaq” on February 07, 2019, also Nasdaq.com with their article: “MacroGenics Up on Lifting of Partial Hold on Cancer Candidate – Nasdaq” published on January 28, 2019, Seekingalpha.com published: “ACADIA Pharmaceuticals Inc. (ACAD) Presents at JPMorgan Healthcare Conference – (Slideshow) – Seeking Alpha” on January 09, 2019. More interesting news about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) were released by: Nasdaq.com and their article: “Is a Beat in Store for Vertex (VRTX) This Earnings Season? – Nasdaq” published on January 30, 2019 as well as Nasdaq.com‘s news article titled: “Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting – Nasdaq” with publication date: January 28, 2019.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Institutional Positions Chart

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *